Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 3, 2015, Pages 857-867

  Lakshminarayana, Suresh B ^a   Huat, Tan Bee ^a   Ho, Paul C ^b   Manjunatha, Ujjini H ^a   Dartois, Véronique ^a,d   Dick, Thomas ^a,c   Rao, Srinivasa P S ^a  

^a NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

In vitro potency; Mycobacterium tuberculosis; Pharmacodynamics

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLAVULANIC ACID; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; SPARFLOXACIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG PENETRATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; GROWTH INHIBITION; IN VITRO STUDY; LIPOPHILICITY; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PLASMA PROTEIN BINDING; VOLUME OF DISTRIBUTION; ANIMAL; CELL LINE; CHEMISTRY; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PERMEABILITY; SOLUBILITY;

ANIMALS; ANTITUBERCULAR AGENTS; CELL LINE; DRUG STABILITY; MACROPHAGES; MICE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MYCOBACTERIUM TUBERCULOSIS; PERMEABILITY; PHYSICOCHEMICAL PHENOMENA; SOLUBILITY;

EID: 84928178295     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku457     Document Type: Article

References (44)

1. Dye C, Williams BG. The population dynamics and control of tuberculosis. Science 2010; 328: 856-61.
2. WHO. Global Tuberculosis Report. Geneva, Switzerland: WHO, 2012. www.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf.
3. Udwadia ZF, Amale RA, Ajbani KK et al. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012; 54: 579-81.
4. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3: 711-5.
5. Lipinski CA, Lombardo F, Dominy BWet al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46: 3-26.
6. Veber DF, Johnson SR, Cheng HYet al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002; 45: 2615-23.
7. Gleeson MP. Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem 2008; 51: 817-34.
8. Egan WJ, Merz KM Jr, Baldwin JJ. Prediction of drug absorption using multivariate statistics. J Med Chem 2000; 43: 3867-77.
9. O'Shea R, Moser HE. Physicochemical properties of antibacterial compounds: implications for drug discovery. J Med Chem 2008; 51: 2871-8.
10. Koul A, Arnoult E, Lounis N et al. The challenge of new drug discovery for tuberculosis. Nature 2011; 469: 483-90.
11. Franzblau SG, DeGroote MA, Cho SH et al. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb) 2012; 92: 453-88.
12. Cooper CB. Development of Mycobacterium tuberculosis whole cell screening hits as potential antituberculosis agents. J Med Chem 2013; 56: 7755-60.
13. Dartois V, Barry CE III. A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorg Med Chem Lett 2013; 23: 4741-50.
14. Brennan PJ, Young DB. Tuberculosis, Handbook of Anti-Tuberculosis Agents, Global Alliance for TB Drug Development. Amsterdam: Elsevier, 2008; 85-170.
15. Budha NR, Lee RE, Meibohm B. Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs. Curr Med Chem 2008; 15: 809-25.
16. Dartois V, Barry CE. Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis. Curr Clin Pharmacol 2010; 5: 96-114.
17. Davies GR, Nuermberger EL. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs. Tuberculosis (Edinb) 2008; 88 Suppl 1: S65-74.
18. Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1984; 9: 511-44.
19. Nuermberger E, Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis 2004; 23: 243-55.
20. Vaddady PK, Lee RE, Meibohm B. In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB. Future Med Chem 2010; 2: 1355-69.
21. Rao SP, Alonso S, Rand L et al. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2008; 105: 11945-50.
22. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996; 64: 2062-9.
23. Gengenbacher M, Rao SP, Pethe K et al. Nutrient-starved, nonreplicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability. Microbiology 2010; 156: 81-7.
24. Kurabachew M, Lu SH, Krastel P et al. Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis. J Antimicrob Chemother 2008; 62: 713-9.
25. Pethe K, Sequeira PC, Agarwalla S et al. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat Commun 2010; 1: 57.
26. Christophe T, Ewann F, Jeon HK et al. High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery. Future Med Chem 2010; 2: 1283-93.
27. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999; 27: 1350-9.
28. Wohnsland F, Faller B. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem 2001; 44: 923-30.
29. Stover CK, Warrener P, VanDevanter DR et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405: 962-6.
30. Diehl KH, Hull R, Morton D et al. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol 2001; 21: 15-23.
31. Tsuji A, Tamai I, Hirooka H et al. b-Lactam antibiotics and transport via the dipeptide carrier system across the intestinal brush-border membrane. Biochem Pharmacol 1987; 36: 565-7.
32. England K, Boshoff HI, Arora K et al. Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2012; 56: 3384-7.
33. Hugonnet JE, Tremblay LW, Boshoff HI et al. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009; 323: 1215-8.
34. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223-7.
35. Kondreddi RR, Jiricek J, Rao SP et al. Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents. J Med Chem 2013; 56: 8849-59.
36. Yokokawa F, Wang G, Chan WL et al. Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active antitubercular agents. ACS Med Chem Lett 2013; 4: 451-5.
37. Ahmad Z, Peloquin CA, Singh RP et al. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother 2011; 55: 239-45.
38. JayaramR, Gaonkar S, Kaur P et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003; 47: 2118-24.
39. Jayaram R, Shandil RK, Gaonkar S et al. Isoniazid pharmacokineticspharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2004; 48: 2951-7.
40. Rouan MC, Lounis N, Gevers T et al. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis. Antimicrob Agents Chemother 2012; 56: 1444-51.
41. Shandil RK, Jayaram R, Kaur P et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007; 51: 576-82.
42. Scaglione F, Paraboni L. Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection. Expert Rev Anti Infect Ther 2006; 4: 479-90.
43. Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol 2014; 12: 159-67.
44. Giuliano C, Jairaj M, Zafiu CM et al. Direct determination of unbound intrinsic drug clearance in the microsomal stability assay. Drug Metab Dispos 2005; 33: 1319-24.